First Patient Dosed in Phase II Trial to Treat Complications in COVID-19
October 16 2020 - 9:30AM
InvestorsHub NewsWire
TORONTO, Ontario, CANADA -- October 16, 2020 --
InvestorsHub NewsWire -- Arch Biopartners Inc. (“Arch” or the
“Company”) (TSX
Venture: ARCH and
OTCQB: ACHFF), announced today it has dosed
the first patient in the Phase II trial of its lead drug LSALT
peptide, targeting prevention of acute lung injury, acute kidney
injury and other complications caused by inflammation in
hospitalized patients with moderate to severe cases of
COVID-19.
The first patient dosed was at the Broward Health Medical Center
in Florida where patient recruitment into the trial continues. Arch
will begin screening and recruiting patients next week at clinical
sites in Louisiana and in Turkey.
About the Phase II trial for LSALT Peptide
The Phase II trial is an international, multicenter, randomized,
double-blind, placebo-controlled, proof of concept study of LSALT
peptide (Metablok) as prevention of organ inflammation known to
trigger acute respiratory distress syndrome (ARDS) and acute kidney
injury (AKI) in patients infected with SARS-CoV-2 (COVID-19).
The composite primary endpoint of the phase II trial reflects
the severe effects often experienced by hospitalized COVID-19
patients and deemed appropriate for LSALT peptide’s novel mechanism
of action in blocking consequential inflammation in the lungs and
kidneys.
The Phase II results will be used to design the Phase III trial,
including greater patient numbers to more fully evaluate efficacy
and safety in COVID patients.
About COVID-19
COVID-19 is the disease caused by the novel coronavirus
SARS-CoV-2 that emerged in China in late 2019. Severe complications
from COVID-19 are in large part due to excessive host immune
responses to the virus that result in progressive lung inflammation
and acute respiratory distress syndrome that often requires
mechanical ventilation and critical care1. Patients with
severe COVID-19 also experience multiple organ dysfunction
including acute kidney injury, liver dysfunction, cardiac failure,
and blood abnormalities. Currently, no approved vaccine or
effective antiviral drug exists for SARS-CoV-2. Treatment of severe
COVID-19 has been primarily supportive, relying heavily on
respiratory, infectious disease and critical care medicine.
Survival rates and health care system capacity could both be
improved with new treatments that prevent the severe manifestations
of COVID-19, such as worsening lung inflammation (ARDS) and AKI
experienced by patients infected with SARS-CoV-2.
1 J. S. Ayres, Sci.
Adv 10.1126/sciadv.abc1518 (2020)
About Arch Biopartners
Arch Biopartners Inc. is a clinical stage company focused on the
development of innovative technologies that have the potential to
make a significant medical or commercial impact. Arch is
developing a pipeline of new drug candidates that inhibit
inflammation in the lungs, liver and kidneys via the dipeptidase-1
(DPEP-1) pathway for multiple medical indications.
For more information on Arch Biopartners, its technologies and
other public documents Arch has filed on SEDAR, please visit
www.archbiopartners.com
The Company has 60,782,302 common shares outstanding.
Forward-Looking Statements
All statements, other than statements of historical fact, in
this news release are forward looking statements that involve
various risks and uncertainties, including, without limitation,
statements regarding the future plans and objectives of the
Company. There can be no assurance that such statements will prove
to be accurate. Actual results and future events could differ
materially from those anticipated in such statements. These and all
subsequent written and oral forward-looking statements are based on
the estimates and opinions of management on the dates they are made
and are expressly qualified in their entirety by this notice. The
Company assumes no obligation to update forward-looking statements
should circumstances or management’s estimates or opinions
change.
The science and medical contents of this release have been
approved by the Company’s Chief Science Officer
The Company is not making any express or implied claims that
its product has the ability to eliminate, cure or contain COVID-19
(or SARS-2 Coronavirus) at this time
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release
ARch Biopartners (QB) (USOTC:ACHFF)
Historical Stock Chart
From Oct 2024 to Nov 2024
ARch Biopartners (QB) (USOTC:ACHFF)
Historical Stock Chart
From Nov 2023 to Nov 2024
